ALPHA-SYNUCLEIN E46K

Alpha-synuclein is a small neuronal protein that plays a central role in Parkinson's disease (PD) pathology. When this protein misfolds and aggregates into clumps called Lewy bodies, it contributes to the death of dopaminergic neurons in the substantia nigra region of the brain, causing the characteristic motor symptoms of PD [1][3]. The E46K mutation (where glutamic acid at position 46 is replaced by lysine) is one of several rare genetic variants that cause familial, early-onset Parkinson's disease, demonstrating that even single amino acid changes can dramatically increase the protein's tendency to form toxic aggregates. The structural prediction of E46K alpha-synuclein using AlphaFold2 yielded an average confidence score (pLDDT) of 59.7, which falls well below the threshold of 70 typically considered reliable for structural interpretation. This low confidence does not represent a failure of the prediction method, but rather reflects an inherent property of alpha-synuclein itself: it is an intrinsically disordered protein that lacks a stable three-dimensional structure in its soluble, monomeric form. The prediction uncertainty is highest because alpha-synuclein exists as a flexible, unfolded chain under normal conditions and only adopts defined conformations when bound to membranes or when aggregating into pathological fibrils [2]. The E46K mutation, which replaces a negatively charged residue with a positively charged one, likely alters the protein's electrostatic properties and increases its propensity to self-associate. Recent research has provided critical insights into how alpha-synuclein aggregation drives neurodegeneration in Parkinson's disease. Studies using preformed fibrils (PFFs) demonstrate that aggregated alpha-synuclein can seed the misfolding of normal protein, creating a self-propagating cascade of pathology [6]. The fragmentation and reaggregation of these fibrils appears to be a key mechanism for spreading pathology, with fibril breakage generating new seeds that can nucleate additional aggregation [2]. This prion-like spreading mechanism may explain how Parkinson's pathology progressively affects different brain regions over time. Cellular models have shown that genetic disruptions affecting lysosomal degradation pathways can exacerbate alpha-synuclein accumulation, suggesting that impaired protein clearance contributes to disease progression [3][5]. The E46K mutation is clinically significant as one of the confirmed genetic causes of autosomal dominant Parkinson's disease, meaning that inheriting just one copy of the mutated gene is sufficient to cause disease. Families carrying this mutation typically develop Parkinson's symptoms at earlier ages than sporadic cases. While the low structural confidence prevents detailed atomic-level analysis of how E46K specifically alters protein folding, the charge reversal at position 46 (from negative to positive) almost certainly affects the protein's aggregation kinetics and may accelerate fibril formation. Understanding these familial mutations remains crucial because they provide definitive proof that alpha-synuclein dysfunction directly causes Parkinson's disease, validating it as a therapeutic target [4][7].